What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Does the data for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?

How do you decide between primary cytoreductive surgery and neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer who appear to be appropriate candidates for either approach?

What adjuvant treatment would you recommend for a patient with recurrent high-grade serous ovarian cancer after secondary cytoreduction to no gross residual disease?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.